E-COMMERCE FUNCTIONALITY TEMPORARILY UNAVAILABLE. US CUSTOMERS PLEASE CALL 1-800-405-3362 TO PLACE AN ORDER.

REPROCELL’s Company News

Press releases, public announcements, and associated material.

 

Recent Company News

1 February 2019 — Appointment of New Distributor in China

10 October 2018 — ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production (PDF)

9 October 2018 — REPROCELL announces the launch of a cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: SNIPER

26 April 2018 — Acquisition of BioServe Biotechnologies India Pvt. Ltd.


Older Company News

15 January 2018 — REPROCELL Launches New Global Website (PDF)

29 November 2017 — REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao (PDF)

29 November 2017 — Presentation: Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao (PDF)

8 November 2017 — REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

10 August 2017 — REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of Its Predictive Drug Discovery Services (PDF)

10 August 2017 — Nicola Sturgeon, First Minister of Scotland, Opens REPROCELL European Headquarters in Glasgow (PDF)

24 May 2017 — REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India (PDF)

13 April 2017 — REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery (PDF)

14 February 2017 — REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan

7 February 2017 — Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination

22 November 2016 — Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products

21 November 2016 — Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy (PDF)

16 November 2016 — Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

11 November 2016 — Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy (PDF)

16 September 2016 — REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex

14 January 2016 — Alvetex in Space

24 November 2015 — REPROCELL Acquires Biopta to Expand Its Drug Discovery Services (PDF)

24 November 2015 — REPROCELL Inc.: Regarding the synergy effect of making Biopta Limited a wholly-owned subsidiary (Supplemental information) (PDF)

11 November 2015 — Regarding the synergy effect of making Biopta Limited a wholly-owned subsidiary (PDF)

18 November 2015 — Notice concerning the publication of a paper concerning “3D culture model construction of mouse neurons” from a company in our group in the international neuroscience journal ‘Neuroscience Letters’ (PDF)

16 November 2015 — A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality (PDF)

4 November 2015 — Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells (PDF)

19 October 2015 — The REPROCELL Group announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by this corporate group and others (PDF)

14 October 2015 — The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal (PDF)

24 September 2015 — Joint Announcement with Ajinomoto Co., Inc. Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells (PDF)

8 September 2015 — REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells (PDF)

26 August 2015 — Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University: New high-performance cryopreservation solution for human ES/iPS cells used in regenerative medicine Notice of the commencement of sales of “ReproCryo DMSO free” (PDF)

14 August 2015 — Commit to Regenerative Medicine (PDF)

14 August 2015 — Presentation: REPROELL Inc.: Advancing Towards Regenerative Medicine (PDF)

14 August 2015 — Announcement: REPROCELL’s project, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells”, has been chosen to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016). The subsidy will be added to the income statement as non-operating income (PDF)

29 July 2015 — Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient” (PDF)

21 July 2015 — Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells (PDF)

1 July 2015 — Announcement: FY 2014-2015 Grant (Additional) for Manufacturing, Commerce, and Service Innovation Has Been Awarded to “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem Cells for Applications in Drug Discovery” (PDF)

30 June 2015 — Stemgent, a REPROCELL Group Company Launches a New High Performance Self-replicative RNA Reprogramming Kit (PDF)

4 June 2015 — REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells (PDF)

5 March 2015 — New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system

9 September 2014 — REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA) (PDF)

5 August 2014 — Stem Cell Company REPROCELL (Japan) Acquires 3D Cell Culture Company Reinnervate (UK) and Human Tissue Supplier BioServe (USA) (PDF)

27 June 2012 — Top award for 3D cell culture pioneer, Stefan Przyborski, of Reinnervate Ltd

Top